Medical Tidbits, International study prompts rethink on the rise of diabetes in cities

Pioneering new research led by University College London (UCL) for the Cities Changing Diabetes partnership shows socio-cultural factors including time pressure, commuting time and where you live play significant roles in diabetes vulnerability1

• Findings from the world’s largest-ever study of urban diabetes – in five cities which together are home to 60 million people – suggest cities must reconsider public health and city planning strategies to address the rise of the condition read more

33 Presentations Evaluating Marketed and Investigational Compounds for Chronic Hepatitis B and Liver Fibrosis —

SAN FRANCISCO–(BUSINESS WIRE)–Nov. 14, 2015– Gilead Sciences, Inc. (Nasdaq:GILD) today announced it will present results from multiple studies of Viread® (tenofovir disoproxil fumarate, TDF) 300 mg for the treatment of chronic hepatitis B virus (HBV) infection, as well as new data regarding its investigational agents for HBV and nonviral liver diseases, including nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), at The Liver Meeting 2015 taking place November 13-17 in San Francisco. – read more

Baxalta to Advance Care for Hemophilia A Patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds

BANNOCKBURN, Ill.–(EON: Enhanced Online News)–Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A. ADYNOVATE is built on the full-length ADVATE [Antihemophilic Factor (Recombinant)] molecule, a leading treatment for hemophilia A with more than 12 years of real-world patient experience. read more

Pharco Pharmaceuticals Inc. Reports Ravidasvir Achieved 100% Cure Rate to Date When Combined with Sofosbuvir for HCV, Non-Cirrhotic, Genotype 4 Patients

ALEXANDRIA, Egypt–(BUSINESS WIRE)–Egypt’s leading drug manufacturer Pharco Pharmaceuticals, Inc. announced advanced results today from its Phase III clinical trial of the combination of ravidasvir with sofosbuvir for the treatment of patients with genotype-4 chronic hepatitis C virus, the largest study of its kind globally.  read more

Swissmedic Approves Xadago® (Safinamide) for Use in Parkinson’s Disease

MILAN–(EON: Enhanced Online News)–Zambon S.p.A., an International Pharmaceutical Company with a strong commitment in central nervous system (CNS) diseases, and its partner Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, today announced that Swissmedic on November 12, 2015, has approved Xadago® (safinamide) as add-on therapy to levodopa (L-dopa) alone or in combination with other PD therapies for patients with Parkinson’s disease in mid-to late-stage and motor fluctuations. read more

NeuroSigma’s Monarch eTNS System Receives CE Mark Approval for ADHD  

LOS ANGELES, Nov. 16, 2015 /PRNewswire/ — NeuroSigma®, Inc. (NeuroSigma) today announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older.  This CE Mark approval is the first for any non-drug treatment of ADHD in the European Union (EU). read more

AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis  

NORTH CHICAGO, Ill., Nov. 14, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new data from its ongoing Phase 3b TOPAZ-II study evaluating VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets), with or without ribavirin (RBV), in adult patients with genotype 1a (GT1a) or genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection.1 Results show that 95 percent (n=586/615) of patients in the TOPAZ-II trial achieved a sustained virologic response at 12 weeks post-treatment (SVR12) after 12 or 24 weeks of treatment, a secondary endpoint for the study.1 These data will be presented at The Liver Meeting® 2015, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. read more

Outcomes After Transplantation are the Same for Patients Who are Obese and Those with Lower BMI

SAN FRANCISCO, Nov. 15, 2015 /PRNewswire/ — Researchers from the Oregon Health & Science University presented a study at the annual meeting of the American Association for the Study of Liver Diseases that calls into question the prevailing practice of excluding morbidly obese patients for liver transplantation.

By examining the U.S. national transplant database, principal investigators Barry Schlansky, MD, MPH; C. Kristian Enestvedt, MD, FACS; and their team observed that obese patients experienced the same risk of dying after liver transplantation as normal weight patients. Past research suggested that very obese patients fare worse after liver transplantation, leading to recommendations to avoid transplant in these patients. The current research shows that there has been an improvement in outcomes for very obese patients receiving liver transplants over the past decade. read more

Med Career News Medical Tidbits

Subscribe today for leading medical news and career advice from top medical recruiters!

 

 

 

 

 

Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.